Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

[1]  R. Buckley,et al.  Results from the First Two Years of the FREEDOM Trial Extension , 2011 .

[2]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[4]  S. Cummings,et al.  Five-year denosumab treatment of postmenopausalwomen with osteoporosis: results of the first twoyears of the freedom trial extension. , 2011 .

[5]  S. Ferrari-Lacraz,et al.  Do RANKL inhibitors (denosumab) affect inflammation and immunity? , 2011, Osteoporosis International.

[6]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Sharmila Majumdar,et al.  Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  H. Genant,et al.  Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. , 2010, Bone.

[9]  Jacques P. Brown,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  P. Kostenuik,et al.  RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies , 2009, Arthritis research & therapy.

[11]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[12]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[13]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  R. Chlebowski,et al.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[16]  C. Brisken,et al.  Epidermal Receptor Activator of NF-κB Ligand Controls Langerhans Cells Numbers and Proliferation12 , 2008, The Journal of Immunology.

[17]  J. S. San Martin,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.

[18]  D. M. van der Heijde,et al.  Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. , 2008, Arthritis and rheumatism.

[19]  P. Kostenuik,et al.  Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses1 , 2007, The Journal of Immunology.

[20]  N. Bishop,et al.  Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL , 2007, Nature Genetics.

[21]  D. Branstetter,et al.  Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. , 2007, Journal of immunology.

[22]  P. Kostenuik,et al.  RANKL inhibition: from mice to men (and women). , 2007, Advances in experimental medicine and biology.

[23]  J. Penninger,et al.  Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells , 2006, Nature Medicine.

[24]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[25]  Steven W. Martin,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  P. Kostenuik,et al.  CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin , 2004, Gut.

[27]  H. Bergmeister,et al.  Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. , 2004, Arthritis and rheumatism.

[28]  R. Faggioni,et al.  Regulatory effects of osteoprotegerin on cellular and humoral immune responses. , 2003, Clinical immunology.

[29]  Yongwon Choi,et al.  TRANCE-RANK Costimulation is Required for IL-12 Production and the Initiation of a Th1-Type Response to Leishmania major Infection in CD40L-Deficient Mice 1 , 2003, The Journal of Immunology.

[30]  H. Bergmeister,et al.  Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. , 2003, Arthritis and rheumatism.

[31]  T. Martin,et al.  Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. , 2002, The American journal of pathology.

[32]  G. Kollias,et al.  Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. , 2002, Arthritis and rheumatism.

[33]  A R Pettit,et al.  TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.

[34]  D L Lacey,et al.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.

[35]  D L Lacey,et al.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[37]  R. Steinman,et al.  TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand–independent T Helper Cell Activation , 1999, The Journal of experimental medicine.

[38]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[40]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[41]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[42]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[43]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[44]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.